| 规格 | 价格 | 库存 | 数量 | 操作 |
|---|---|---|---|---|
| 1mg | ¥2,057.00 | 现货 | 1 | |
| 5mg | ¥4,041.00 | 现货 | 1 | |
| 10mg | ¥7,200.00 | 现货 | 1 | |
| 20mg | ¥12,489.00 | 现货 | 1 |
ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.
ABT-072 inhibits non-nucleoside NS5B polymerase, and yields antiviral effects[1].
[1]. Min Gao, et al. Combinations of Hepatitis C Virus Inhibitors. US 20120196794 A1
Cell experiment: | To determine compound efficacy, HCV replicon cells are plated at a density of 104 per well in 96-well plates in DMEM media containing 10% FBS. Following incubation overnight, compounds serially diluted in DMSO, or DMSO alone, are added to individual wells to a final DMSO concentration of 0.5%. Cell plates are then incubated at 37°C. for 3 days prior to assaying for cytotoxicity and HCV inhibition. Cell viability is measured using an Alamar Blue assay and CC50 values are calculated using the median effect equation. |
References: [1]. Min Gao, et al. Combinations of Hepatitis C Virus Inhibitors. US 20120196794 A1 |
